1. Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting
- Author
-
Zhuo-Yu An and Xiao-Hui Zhang
- Subjects
Menin inhibitors ,Acute myeloid leukemia ,Revumenib ,Ziftomenib ,Clinical trials ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings underscore the potential of menin inhibitors in transforming AML treatment, particularly in genetically defined subgroups, offering hope for improved patient outcomes. Ongoing studies, like KOMET-008, further explore the synergistic potential of menin inhibitors in combination regimens, shaping future AML management strategies.
- Published
- 2024
- Full Text
- View/download PDF